Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
Completed
- Conditions
- PEComaHemangioma
- Registration Number
- NCT02334930
- Lead Sponsor
- University Hospital, Bordeaux
- Brief Summary
PEComa is rare tumor affecting particularly patients with Tuberous Sclerosis. Biological similarities were seen between PEComa and infantile hemangioma. Propranolol is highly efficient to treat infantile hemangioma and we believe that this drug can also be useful for the treatment of PEComa.
Purpose : to understand the mechanism of action of propranolol in PEComas and related pediatric vascular lesions and to select possible novel targets of betablockers in vascular tumors related to PEComas by using YAP oncogene activation as a molecular marker
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
- patients who will have biopsy or surgery for PEComa or vascular pediatric tumor (RICH, NICH, hemangioma or pyogenic granuloma)
- A free, informed and written consent will be established
Exclusion Criteria
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method YAP cellular expression by immunohistochemistry study on collected tissues At inclusion (day 0)]
- Secondary Outcome Measures
Name Time Method Beta adrenergic receptors expression by immunohistochemistry study on collected tissues At inclusion (day 0)] Study of Hippo/YAP pathway expression by western-blot, and correlation with propranolol efficacy At inclusion (day 0)] Study of MAP/kinases pathway expression by western-blot, and correlation with propranolol efficacy At inclusion (day 0)] Study of PKA/AMPc pathway expression by western-blot, and correlation with propranolol efficacy At inclusion (day 0)]
Trial Locations
- Locations (1)
CHU de Bordeaux
🇫🇷Bordeaux, France
CHU de Bordeaux🇫🇷Bordeaux, France